Drugs / Autologous adipose tissue stromal vascular fraction
Autologous adipose tissue stromal vascular fraction
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01885832 | Jun 2013 → Jul 2016 | osteoarthritis | Translational Biosciences | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02142842 | Apr 2013 → Dec 2015 | osteoarthritis, knee | University of Science Ho Chi Minh City | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous adipose tissue stromal vascular fraction | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01885832 ↗ |
| Known as | Autologous stromal vascular cells | “patients will be treated with a single dose of autologous stromal vascular cells (SVF) in combination with platelet rich plasma (PRP).” NCT02142842 ↗ |
| Known as | autologous stromal vascular fraction | “autologous stromal vascular fraction (SVF)” NCT01885832 ↗ |
| Known as | SVF | “patients will be treated with a single dose of autologous stromal vascular cells (SVF) in combination with platelet rich plasma (PRP).” NCT02142842 ↗1“autologous stromal vascular fraction (SVF)” NCT01885832 ↗ |
| Modality | Cell therapy | “single dose of autologous stromal vascular cells (SVF)” NCT01885832 ↗ |
| Route | Other | “via intra-articular injection” NCT01885832 ↗ |